Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.